Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio

By on    Pharma Industry News  

Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio

In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar medicines, announced its strategic acquisition of the US biosimilar ranibizumab, CIMERLI, from Coherus BioSciences, Inc. The deal, valued at an upfront cash purchase of USD 170 million, encompasses a biologics license application, product inventory, specialized ophthalmology sales […]

FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11

By on    Pharma Industry News  

FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11

Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ophthalmology biosimilar referencing Genentech’s Lucentis (ranibizumab). Ranibizumab is an anti vascular endothelial growth factor (VEGF) therapy for retinal vascular disorders, which are a major cause of blindness in the US. […]